Anti-VEGF therapy did not maintain visual acuity gains in AMD patients at 5 years

SEATTLE — Patients with neovascular age-related macular degeneration who were treated with anti-VEGF therapy did not maintain visual gains at 5 years, according to the Comparison of Age-Related Macular Degeneration Treatment Trials results presented here. “Our primary goal of the CATT follow-up study was to assess the overall visual acuity and morphologic outcomes at 5 years of any anti-VEGF treatment,” Daniel F. Martin, MD, said at the Association for Research in Vision and Ophthalmology meeting.

Telemedicine improves detection, management of glaucoma

SEATTLE — Community-based telemedicine can improve detection and management of patients with high-risk glaucoma and other diseases, according to a poster presented here.The Wills Eye Glaucoma Research Center initiated a 5-year community-based telemedicine intervention to improve the detection and management of high-risk glaucoma patients in Philadelphia, Lisa A. Hark, MD, and colleagues said at the Association for Research in Vision and Ophthalmology meeting.